Press releases - CombiGene

Press releases

February 14, 2025

Year-end report January-December 2024 CombiGene AB (Publ)

January 28, 2025

Discontinuation of research activities

January 9, 2025

Stockslätten AB acquires all shares from Strategic Partners A/S

January 9, 2025

Clarification regarding the management’s role during the restructuring period

January 9, 2025

CombiGene initiates restructuring as part of strategic review to maximize shareholder value

December 17, 2024

CombiGene AB (publ): Nominating committee

December 10, 2024

Bulletin from the Extraordinary General Meeting of CombiGene AB (publ)

December 2, 2024

CombiGene conducts Extraordinary General Meeting

2023

December 20, 2023

Eurostars contributes SEK 8,7 million to the financing of the COZY01 pain project

November 27, 2023

New issue of Ingeneious, no 5 2023

November 10, 2023

Interim report January – September 2023 for CombiGene AB (publ)

October 31, 2023

CombiGene chooses Charles River as preclinical toxicology partner for COZY01 pain project

October 26, 2023

CombiGene and Zyneyro choose initial indication in the COZY01 pain project

October 25, 2023

CombiGene AB (publ): Nominating committee

October 14, 2023

Spark Therapeutics terminates collaboration agreement for the epilepsy project CG01 with CombiGene

September 15, 2023

CombiGene chooses CDMO partner for the COZY01 pain project

2022

November 11, 2022

Interim report January – September 2022 for CombiGene AB (publ)

November 10, 2022

CombiGene AB (publ): Nominating committee

November 4, 2022

New issue of Ingeneious, no 3 2022

September 27, 2022

CombiGene strengthens its management capacity through the recruitment of Peter Ekolind as COO

August 25, 2022

Interim report January – June 2022 for CombiGene AB (publ)

June 23, 2022

GeneNova collaboration to develop adeno-associated virus based gene therapies

June 22, 2022

New issue of Ingeneious, no 2:3 2022

June 16, 2022

New issue of Ingeneious, no 2:2 2022

2021

December 16, 2021

CombiGene and Spark Therapeutics plan to expand the clinical development program to include the U.S. as well as Europe

November 15, 2021

CombiGene AB (publ): Nominating committee

November 12, 2021

Interim report January – September for CombiGene AB (publ)

November 1, 2021

CombiGene’s Horizon 2020 project successfully completed

October 18, 2021

New issue of Ingeneious no 3 2021

October 12, 2021

CombiGene and Spark Therapeutics enter exclusive, global licensing agreement for gene therapy candidate CG01

August 25, 2021

CombiGene applies for international patent protection for the vectors developed within the CGT2 project

August 20, 2021

Interim report January – June 2021 for CombiGene AB (publ)

2020

December 14, 2020

With the recruitment of Martin Linhult, CombiGene is starting the process to strengthen the company in preparation for the clinical studies in the epilepsy project CG01

December 4, 2020

CombiGene’s research is recognized internationally after careful scientific review

December 2, 2020

CombiGene’s warrants of series TO4 and TO5 utilized to 98.4 per cent

November 25, 2020

CombiGene, together with gene therapy manufacturer Viralgen, has successfully completed the first large-scale production of CG01

November 24, 2020

Major shareholders and management demonstrate their faith in CombiGene by participating in the warrants of series TO4 and TO5

November 23, 2020

CombiGene signs agreement with British Neurochase for optimized administration of CG01, a gene therapy developed for treatment of focal epilepsy

November 19, 2020

CombiGene AB (publ): Nominating committee

November 18, 2020

Horizon 2020 continues to invest in CombiGene´s epilepsy project

2019

December 19, 2019

Study in human brain tissue shows that NPY can suppress epileptic activity via Y2-receptor activation

December 16, 2019

New issue of CombiGenes newsletter Ingeniouis

November 26, 2019

CombiGene’s Chairman and CEO increase their shareholdings in the company

November 20, 2019

Professor Merab Kokaia’s proof-of-concept study has been published in Molecular Therapy: Methods & Clinical Development

November 18, 2019

CombiGene receives a second payment of EUR 1.21 million from Horizon 2020

November 13, 2019

Outcome of exercise of warrants in CombiGene

October 24, 2019

CombiGene carries out a directed new issue of shares to Lipigon Pharmaceuticals

October 16, 2019

CombiGene launches new website

2018

December 17, 2018

CombiGene approved for listing on Nasdaq First North Stockholm and first day of trading is Wednesday 19 December 2018

December 17, 2018

CombiGene approved for listing on Nasdaq First North Stockholm and first day of trading is Wednesday 19 December 2018

December 14, 2018

Ingeneious #5 2018, News from CombiGene

December 14, 2018

New issue of CombiGene’s newsletter Ingenious

December 14, 2018

CombiGene featured in an article in Nature, one of the world’s leading scientific journals

December 14, 2018

CombiGene featured in a major article in Nature, one of the world’s leading scientific journals

December 11, 2018

January 29, Lund Aktiedagen

December 10, 2018

April 4, National ATMP Conference 2019, Göteborg

2017

December 22, 2017

Another gene therapy product was approved by the FDA

December 14, 2017

Study with brain tissue from human epilepsy patients confirms that brain cells express CombiGene’s candidate drug CG01

December 7, 2017

Initial data from the long-term study on CombiGene’s candidate drug for treating epilepsy indicate positive effects in the form of fewer seizures.

November 30, 2017

Ingeneious #4 2017, News from CombiGene

November 29, 2017

Interview with Merab Kokaia concerning CombiGene’s long-term study

November 23, 2017

CombiGene attended “Advanced Therapies Investor Day” in London

November 8, 2017

CombiGene has today launched its new website www.combigene.com

November 1, 2017

Interim Report January-September 2017